1
|
Alum EU, Tufail T, Uti DE, Aja PM, Offor CE, Ibiam UA, Ukaidi CUA, Alum BN. Utilizing Indigenous Flora in East Africa for Breast Cancer Treatment: An Overview. Anticancer Agents Med Chem 2025; 25:99-113. [PMID: 39297456 DOI: 10.2174/0118715206338557240909081833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Revised: 08/16/2024] [Accepted: 08/23/2024] [Indexed: 02/18/2025]
Abstract
BACKGROUND Breast cancer is a significant global health challenge, contributing substantially to cancer- related deaths. Conventional treatment methods, including hormone therapy, chemotherapy, surgical interventions, and radiation, have long been utilized. However, these traditional treatments are often associated with serious side effects and drug resistance, limiting their efficacy. AIM This review aims to explore the potential of medicinal plants used in breast cancer management in East Africa, focusing on their bioactive compounds and anticancer properties. METHODS A comprehensive literature search was conducted to examine the effectiveness of medicinal plants in treating breast cancer across Kenya, Ethiopia, Uganda, Tanzania, and Rwanda. Relevant studies published between 2003 and 2023 were identified using keywords related to breast cancer and medicinal plants. The search was performed across multiple databases, including Google Scholar, PubMed, Scopus, Web of Science Core Collection, and Science Direct. RESULTS Numerous natural compounds found in East African medicinal plants including Cymbopogon citratus (Lemongrass,) Tabebuia avellanedae, Prunus africana (African Cherry), Euclea divinorum, Berberis holstii, Withania somnifera (Ashwagandha, Curcuma longa (Turmeric), Garcinia mangostana (Mangosteen, Vitis vinifera (Grapevine), Eugenia jambolana (Java Plum), Moringa oleifera (Drumstick Tree), Camellia sinensis (Tea), Glycine max (Soybean), Catharanthus roseus, Madagascar Periwinkle), Rhus vulgaris (Wild Currant) exhibit significant anticancer properties. These compounds have demonstrated the ability to reduce breast cancer aggressiveness, inhibit cancer cell proliferation, and modulate cancer-related pathways. Current research focuses on these natural and dietary compounds to develop more effective strategies for treating breast cancer. CONCLUSION The findings suggested that East African medicinal plants hold promise as complementary treatments for breast cancer, offering potential benefits such as affordability, cultural appropriateness, and sustainability. Further research into these plants and their bioactive compounds could revolutionize breast cancer treatment, improving survival rates and addressing the rising incidence of breast cancer-related fatalities. Other: The review underscores the importance of continued research, conservation, and the integration of ancient healing methods to fully harness the potential of East African flora in breast cancer management.
Collapse
Affiliation(s)
- Esther Ugo Alum
- Department of Research and Publications, Kampala International University, Kampala, P. O. Box 20000, Uganda
- Department of Biochemistry, Faculty of Science, Ebonyi State University, P.M.B. 053 Abakaliki, Ebonyi State, Nigeria
| | - Tabussam Tufail
- School of Food and Biological, Engineering Jiangsu, University Zhenjiang Kampala, China
- University Institute of Diet and Nutritional Sciences, The University of Lahore, Lahore, Pakistan
| | - Daniel Ejim Uti
- Department of Research and Publications, Kampala International University, Kampala, P. O. Box 20000, Uganda
- Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, Federal University of Health Sciences, Otukpo, Benue State, Nigeria
| | - Patrick Maduabuchi Aja
- Department of Biochemistry, Faculty of Science, Ebonyi State University, P.M.B. 053 Abakaliki, Ebonyi State, Nigeria
- Department of Biochemistry, Kampala International University, Western Campus, Kampala, Uganda
| | - Christian Emeka Offor
- Department of Biochemistry, Faculty of Science, Ebonyi State University, P.M.B. 053 Abakaliki, Ebonyi State, Nigeria
| | - Udu Ama Ibiam
- Department of Biochemistry, Faculty of Science, Ebonyi State University, P.M.B. 053 Abakaliki, Ebonyi State, Nigeria
- Department of Biochemistry, College of Science, Evangel University Akaeze, Abakaliki, Ebonyi State, Nigeria
| | - Chris U A Ukaidi
- College of Economics and Management, Kampala International University, Kampala, Uganda
| | - Benedict Nnachi Alum
- Department of Research and Publications, Kampala International University, Kampala, P. O. Box 20000, Uganda
| |
Collapse
|
2
|
Wang H, Hao R, Liu W, Zhang Y, Ma S, Lu Y, Hu J, Qi Y. Identification of transcription factors associated with the disease-free survival of triple-negative breast cancer through weighted gene co-expression network analysis. Cytojournal 2024; 21:71. [PMID: 39917004 PMCID: PMC11801659 DOI: 10.25259/cytojournal_127_2024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2024] [Accepted: 10/31/2024] [Indexed: 02/09/2025] Open
Abstract
Objective Triple-negative breast cancer (TNBC) is a subtype of breast cancer that has a worse prognosis than the other subtypes of breast cancer because of its high recurrence and metastasis rates. The objective of this study is to identify the regulatory factors that are associated with the disease-free survival (DFS) of TNBC and potential biomarkers for TNBC treatment. Material and Methods We obtained the GSE97342 dataset from the Gene Expression Omnibus website and conducted weighted gene co-expression network analysis (WGCNA) to identify modules associated with the DFS of TNBC. Subsequently, biological functions of the modules were elucidated through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Cross-checking with the Human Transcription Factor Database facilitated the selection of hub transcription factors through univariate Cox regression analysis of overlapping transcription factors. Utilizing bioinformatics analysis, we assessed the prognostic significance of these hub transcription factors, investigated their target genes, and explored their associations with tumor immune cells in TNBC. Finally, the expression levels of the hub transcription factors were validated by immunohistochemical staining, quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western blotting. Results Through WGCNA analysis, we identified three modules correlated with DFS in TNBC. GO and KEGG analyses elucidated the biological functions of genes within these modules. Survival analysis pinpointed three hub transcription factors: Forkhead box D1 (FOXD1), aryl hydrocarbon receptor nuclear translocator 2 (ARNT2), and zinc finger protein 132 (ZNF132). The expression level of FOXD1 was negatively associated with the prognoses of patients with TNBC, whereas the other two genes were positively associated with the prognoses of patients with TNBC. Immunohistochemical staining, qRT-PCR, and Western blotting validated the expression levels of the hub transcription factors. Conclusion We discovered three hub transcription factors (FOXD1, ARNT2, and ZNF132) that were correlated with the DFS of TNBC. These correlations suggested their potential as prognostic predictors for patients with TNBC.
Collapse
Affiliation(s)
- Huipo Wang
- Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Ran Hao
- Health Research Institute, Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Wei Liu
- Department of Immunology, School of Basic Medicine, Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Yi Zhang
- Department of Cancer Genetics and Epigenetics, City of Hope National Medical Center, Duarte, California, United States
| | - Shen Ma
- Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Yiwei Lu
- Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Jie Hu
- School of Public Health, Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Yixin Qi
- Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
| |
Collapse
|
3
|
Musavi H, Iraie R, Mohammadi M, Barartabar Z, Yazdi M, Bagheri A, Khonakdar-Tarsi A. Investigating the Effect of Galbanic Acid on Lipin-1 and Lipin-2 Genes in Fatty Liver Cells with Palmitate. Adv Biomed Res 2024; 13:106. [PMID: 39717250 PMCID: PMC11665169 DOI: 10.4103/abr.abr_456_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 01/28/2024] [Accepted: 01/31/2024] [Indexed: 12/25/2024] Open
Abstract
Background Non-alcoholic fatty liver disease is related to lipid accumulation and inflammation. Considering the role of lipin-1 and lipin-2 in fat homeostasis and inflammation, this study aimed to explore the effect of galbanic acid (Gal) and resveratrol (RSV) on alterations in the gene expression levels and protein abundance of lipin-1 and lipin-2 in HepG2 liver cells lipid-enriched with palmitate (Pal). Materials and Methods HepG2 cells were subjected to different amounts of Gal and RSV for 24 hours in the presence of Pal to induce lipid accumulation. The RT-PCR method was employed to assess the expression of lipin-1 and lipin-2 genes, while protein levels were evaluated by western blot analysis. Lipid accumulation was determined qualitatively and semi-quantitatively using the oil-red staining technique. Results Gal treatment increased lipin-1 and lipin-2 gene expression (P < 0.05). In contrast, the groups treated with RSV did not show a substantial variance in the expression levels of the two genes (P > 0.05). In the groups treated with Gal/RSV, the intensity of lipin-2 protein bands was higher compared to the Pal group (P > 0.01); however, the intensity of lipin-1 protein bands was not significantly different (P > 0.05). Conclusion Gal, a coumarin compound, significantly increased the expression of lipin-1 and lipin-2 in HepG2 cells treated with Pal. Consequently, this research suggests gal as a novel strategy for regulating fat homeostasis in HepG2 cells.
Collapse
Affiliation(s)
- Hadis Musavi
- Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
- Department of Medical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Reza Iraie
- Department of Medical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Maryam Mohammadi
- Health System Research, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
| | - Zeinab Barartabar
- Department of Clinical Biochemistry, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran
| | - Mohammad Yazdi
- Department of Clinical Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Abouzar Bagheri
- Department of Clinical Biochemistry and Medical Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Abbas Khonakdar-Tarsi
- Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
- Department of Medical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|
4
|
Azad M, Hosseini F, Hassanzade H, Gharedaghi S, Mahdipour E, Rassouli FB, Jamialahmadi K. Galbanic acid suppresses melanoma cell migration and invasion by reducing MMP activity and downregulating N-cadherin and fibronectin. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2024; 397:5779-5788. [PMID: 38324091 DOI: 10.1007/s00210-024-02981-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 01/24/2024] [Indexed: 02/08/2024]
Abstract
High mortality rate of melanoma is due to the metastasis of malignant cells. Galbanic acid (GBA) is a natural sesquiterpene coumarin with valuable pharmaceutical activities. Our study aimed to investigate whether GBA can affect the migration, invasion, and adhesion of melanoma cells. The survival rate of B16F10 cells was measured using the alamarBlue assay. Scratch, adhesion, and invasion assays were performed to determine the effect of GBA on metastatic behavior of cells. Moreover, gelatin zymography was done to assess the activity of MMP-2 and MMP-9, and qRT-PCR was used to investigate the effect of GBA on the expression of candidate genes. Based on the results of alamarBlue assay, 40 µM GBA was chosen as the optimum concentration for all tests. Our findings indicated that GBA significantly decreased the invasion and migration of B16F10 cells while enhancing their adhesion ability. In addition, gelatin zymography demonstrated that GBA reduced the enzymatic activity of MMP-2 and MMP-9. Moreover, qRT-PCR revealed that GBA reduced the expression of N-cadherin and fibronectin. Current findings demonstrated, for the first time, that GBA inhibited the migration and invasion of melanoma cells via reducing the activity of MMP-2 and MMP-9 and downregulating N-cadherin and fibronectin expression. Accordingly, GBA could be suggested as a potential therapeutic agent for the treatment of melanoma.
Collapse
Affiliation(s)
- Masoumeh Azad
- Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Fatemehsadat Hosseini
- Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Halimeh Hassanzade
- Stem Cell and Regenerative Medicine Research Group, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi, Mashhad, Iran
| | - Shahin Gharedaghi
- Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Elahe Mahdipour
- Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Fatemeh B Rassouli
- Novel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
| | - Khadijeh Jamialahmadi
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
5
|
Dehghanzad M, Mohammadi M, Nejati M, Pouremamali F, Maroufi NF, Akbarzadeh M, Samadi N, Nouri M. The potential therapeutic effect of melatonin in oxaliplatin combination therapy against chemoresistant colorectal cancer cells. Mol Biol Rep 2024; 51:348. [PMID: 38401018 DOI: 10.1007/s11033-024-09316-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 02/02/2024] [Indexed: 02/26/2024]
Abstract
BACKGROUND Oxaliplatin is one of the main therapeutics in colorectal cancer (CRC) chemotherapy. However, in light of multidrug resistance (MDR) phenotype development, the efficacy of oxaliplatin has decreased. This study aimed to assess the potential therapeutic effect of melatonin in oxaliplatin combination therapy for drug-resistant colorectal cancer cells. METHODS AND RESULTS Initially, the oxaliplatin-resistant cell line was created of LS174T (LS174T/DR) by using the oxaliplatin IC50 concentration and resting cycles. MTT assays and flow cytometry were applied for assessing cell viability and apoptotic cells. The mRNA expression level of Bax, Bcl2, MT1, MT2, and ABCB1 as well as protein levels of ABCB1, Bcl2, BAX were measured by the qRT-PCR and western blot techniques respectively. P-gp activity was assessed by Rho123 staining. The IC50 concentration of oxaliplatin in resistant cells was increased from 500.7 ± 0.2 nM to 7119 ± 0.1 nM. Bcl2, MT1, MT2, and ABCB1 mRNA plus protein expression levels of Bcl2 and ABCB1 were significantly reduced in resistant cells, along with a marked increase in Bax mRNA and protein levels compared to parental cells. Rho 123 staining revealed a marked reduction in P-gp activities in the combination-treated group compared to the oxaliplatin-treated group. CONCLUSIONS The results of cytotoxicity assays, MTT, and flow cytometry revealed that the combination of melatonin and oxaliplatin exerts synergistic effects on induction of oxaliplatin's cytotoxicity in CRC. Our research suggests that combining the treatments of melatonin and oxaliplatin may be considered as a new approach to overcoming oxaliplatin resistance in CRC patients.
Collapse
Affiliation(s)
- Masoumeh Dehghanzad
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Gholgasht Ave, Tabriz, Iran
| | - Mohammad Mohammadi
- Department of Medical Laboratory Science, Faculty of Medicine, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran
| | - Mohaddeseh Nejati
- Department of Biology, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran
| | - Farhad Pouremamali
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Nazila Fathi Maroufi
- Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Gholgasht Ave, Tabriz, Iran
- Department of Human Genetics, McGill University, Montreal, Canada
- Victor Philip Dahdaleh Institute of Genomic Medicine at McGill University, Montreal, Canada
| | - Maryam Akbarzadeh
- Department of Biochemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Naser Samadi
- Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Gholgasht Ave, Tabriz, Iran
| | - Mohammad Nouri
- Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Gholgasht Ave, Tabriz, Iran.
| |
Collapse
|